[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.241.199. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News and Perspectives
April 6, 2005

Pharmaceutical Industry Funding for Residencies Sparks Controversy

JAMA. 2005;293(13):1572-1580. doi:10.1001/jama.293.13.1572

A controversial American Academy of Dermatology (AAD) pilot program that aims to boost the number of dermatology residencies using funding from pharmaceutical companies and other sources has left some physicians questioning the need for more dermatologists and the wisdom of allowing pharmaceutical support for graduate medical education.

On November 12, 2004, the AAD announced the initiative, which will pool money donated by the academy, pharmaceutical companies, and other interested parties to fund 10 new dermatology residency slots for the July 2006 match. In late January, the AAD board decided to expand the initiative to seek other possible solutions to a perceived shortage such as the use of nurse practitioners and other such staff or training for primary care physicians.

First Page Preview View Large
First page PDF preview
First page PDF preview
×